Meeder Advisory Services’s AstraZeneca AZN Stock Holding History

Meeder Advisory Services’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$227K	Sell	1,150 -22	-2%	-$4.24K	0.01%	613
2025 Q4	$215K	Buy	+1,172	New	+$206K	0.01%	626
2024 Q3	–	Sell	-1,319	Closed	-$206K	–	557
2024 Q2	$206K	Buy	+1,319	New	+$198K	0.01%	488

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Meeder Advisory Services's AZN Position: Q1 2026 in Review

Meeder Advisory Services reduced its AstraZeneca (AZN) stake by 1.9% in Q1 2026, selling an estimated $4.24K and leaving 1,150 shares worth $227K. The position accounts for 0.01% of the portfolio, ranked #613.

Meeder Advisory Services first reported a position in AZN in Q2 2024 and has held it in 3 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Meeder Advisory Services held 1,150 shares of AstraZeneca worth $227K as of Q1 2026.
Meeder Advisory Services sold 22 AstraZeneca shares in Q1 2026, an estimated $4.24K.
AstraZeneca made up 0.01% of Meeder Advisory Services's portfolio in Q1 2026, its #613 holding.
Meeder Advisory Services first reported a position in AstraZeneca in Q2 2024 and has held it in 3 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Meeder Advisory Services's 13F filing for Q1 2026, filed 7 May 2026.